0
Post your comment
Last update: 20 October 2017
Eculizumab is a humanized monoclonal antibody that is a terminal complement inhibitor. It is used to treat people with paroxysmal nocturnal haemoglobinuria (PNH), for whom it improves quality of life but does not appear to affect the risk of death. It is also indicated for the treatment of patients with atypical haemolytic uremic syndrome (aHUS) – a disease that primarily affects kidney function – to inhibit complement-mediated thrombotic microangiopathy.
The originator product, Soliris (eculizumab), made by Alexion Pharmaceuticals, was approved by the US Food and Drug Administration (FDA) on 16 March 2007 for the treatment of PNH and on 23 September 2011 for the treatment of aHUS. It was approved by the European Medicines Agency (EMA) for the treatment of PNH on 20 June 2007 and on 24 November 2011 for the treatment of aHUS [1]. Soliris had worldwide net sales of US$2.6 billion in 2015, making it a lucrative target for biosimilars developers, see Table 1.
The patents on Soliris will expire in the US on 16 March 2021 and in Europe on 1 May 2020 [1]. Some of the eculizumab biosimilars and non-originator biologicals* approved or in development are presented in Table 1.
Table 1: Biosimilars and non-originator biologicals* of eculizumab approved or in development
| Company name, Country | Product name | Stage of development |
| Actavis/Amgen, USA | ABP 959 | Developing a biosimilar in collaboration [2] |
| Epirus Biopharmaceuticals, USA | BOW080 | Preclinical. Epirus expects to file for approval of BOW080 in 2020 [3] |
| *See editor’s comment | ||
On 9 May 2016, Epirus Biopharmaceuticals announced that it was re-prioritizing its pipeline to solely focus on biosimilars to treat rare diseases. These include BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar).
Editor’s comment
It should be noted that ‘non-originator biologicals’ approved outside Europe might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. The EMA (European Medicines Agency) regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.
Related articles
Biosimilars of basiliximab
References
1. Derbyshire M. Patent expiry dates for biologicals: 2016 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(1):27-30. doi:10.5639/gabij.2017.0601.006
2. GaBI Online - Generics and Biosimilars Initiative. Amgen’s biosimilar plans [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Oct 20]. Available from: www.gabionline.net/Biosimilars/News/Amgen-s-biosimilar-plans
3. GaBI Online - Generics and Biosimilars Initiative. Epirus expands biosimilars pipeline with Bioceros acquisition [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 May 19]. Available from: www.gabionline.net/Pharma-News/Epirus-expands-biosimilars-pipeline-with-Bioceros-acquisition
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Source: Alexion Pharma, EMA, Epirus
Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Sign up today for the weekly briefing on the latest developments in generic and biosimilar medicines!
Post your comment